Summit Therapeutics Inc. — Director's Dealing 2023

Mar 13, 2023

SEC Form 4/A — Form 4/A

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2023-03-08

Reporting Person: Zanganeh Mahkam (Director, Co-CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-08	Common Stock	P	16778415	$1.05	Acquired	24573798	Indirect
2023-03-08	Common Stock	P	6748629	$1.05	Acquired	9884095	Indirect

Footnotes

F1: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.

F2: Includes the number of shares of Common Stock that were inadvertently previously disclosed as being held by Dr. Zanganeh personally, which are held by the Mahkam Zanganeh Revocable Trust. Dr. Zanganeh does not directly hold any shares personally, all of her shares are held through the Mahkam Zanganeh Revocable Trust.

F3: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.